Zymeworks (ZYME) Research & Development (2021 - 2026)
Zymeworks (ZYME) posted Research & Development of $34.5 million for Q1 2026, up 10.32% sequentially from $31.2 million in Q4 2025, and down 3.58% YoY from $35.7 million in Q1 2025.
Zymeworks (ZYME) Research & Development (2021 - 2026) Analysis & Trends
Zymeworks has reported Research & Development for 6 years, with the latest figure at $34.5 million in Q1 2026.
- Quarterly Research & Development fell 3.58% year-over-year to $34.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.7 million (down 1.88% YoY) and the FY2025 annual result came in at $137.0 million, up 1.77% from the prior year.
- Research & Development advanced to $34.5 million in Q1 2026 per ZYME's latest filing, from $31.2 million in the prior quarter.
- Over five years, Research & Development peaked at $62.5 million in Q1 2022 and troughed at $25.5 million in Q4 2023.
- A 5-year average of $38.7 million and a median of $35.7 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development plunged 51.81% in 2023, then soared 45.21% in 2024.
- Over 5 years, Research & Development stood at $53.0 million in 2022, then slumped by 51.81% to $25.5 million in 2023, then jumped by 45.21% to $37.1 million in 2024, then dropped by 15.72% to $31.2 million in 2025, then advanced by 10.32% to $34.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $34.5 million, $31.2 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | 27.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.44 Mn |
| Mar 31, 2026 | 34.46 Mn |
| Dec 31, 2025 | 31.24 Mn |
| Sep 30, 2025 | 35.58 Mn |
| Jun 30, 2025 | 34.45 Mn |
| Mar 31, 2025 | 35.74 Mn |
| Dec 31, 2024 | 37.06 Mn |
| Sep 30, 2024 | 36.35 Mn |
| Jun 30, 2024 | 29.16 Mn |
| Mar 31, 2024 | 32.04 Mn |
| Dec 31, 2023 | 25.52 Mn |
| Sep 30, 2023 | 32.78 Mn |
| Jun 30, 2023 | 39.41 Mn |
| Mar 31, 2023 | 45.91 Mn |
| Dec 31, 2022 | 52.97 Mn |
| Sep 30, 2022 | 37.10 Mn |
| Jun 30, 2022 | 56.02 Mn |
| Mar 31, 2022 | 62.51 Mn |
| Dec 31, 2021 | 54.87 Mn |
| Sep 30, 2021 | 49.89 Mn |